Kymera Investor Day Presentation Deck
Pvalue (-log 10)
3
2.5
1.5
1
0.5
0
-2
KT-474: Potent and Specific IRAK4 Degradation with Impact on
Cytokines Superior to Kinase Inhibition
Degradation and Selectivity
10xDC90
IRAK4
-1.5
-1 -0.5 0
KYMERA
0.5
1
24hr
pval=0.05
1.5 2
Protein Level Fold Change (log2)
©2021 KYMERA THERAPEUTICS, INC.
●
KT-474 DC50 = 2.1 nM in
human immune cells
●
• KT-474 only degraded
IRAK4 in human immune
cells at concentration 10-
fold above the DC90
●
KT-474 better able to
inhibit IL-6 under both LPS
and LPS + IL-1ẞ than
clinically active IRAK4 SM
kinase inhibitor
PF-06550833
KYMERA R&D DAY - December 16th, 2021
150
100
50
Superiority over SM kinase Inhibitor
LPS + IL-1B → IL-6
HA
-4
HA
Legend Compound
101
-2
e
Log[Compound] (nM)
0
IRAK4 Degrader
Negative control
IRAK4 SMI (PF-06550833)
IL-6 IC50 (nM)
0.8
450
N/A
PAGE 24View entire presentation